Roy Sampson
Rheumatology · Lowell, ARNPI 1568686723
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 496 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.5% — the pattern of someone who eats at a lot of different presentations.
Across 496 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$2K
- UCB, Inc.$1K
- Pfizer$787
- Johnson & Johnson$459
- Lilly USA, LLC$315
- plus $2K from 15 others
What the payments were for
- Food & beverage$8,34699%
- Education$531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 129 | $1,971 |
| Amgen(2 entities) | 103 | $1,819 |
| UCB, Inc. | 40 | $1,042 |
| Pfizer | 60 | $787 |
| Johnson & Johnson | 25 | $459 |
| Lilly USA, LLC | 21 | $315 |
| Novartis | 16 | $278 |
| GSK | 16 | $274 |
| Genentech USA, Inc. | 14 | $263 |
| E.r. Squibb & Sons, L.L.C. | 17 | $257 |
| Boehringer Ingelheim | 15 | $242 |
| AstraZeneca | 9 | $164 |
| Sanofi | 6 | $108 |
| Antares Pharma, Inc. | 7 | $104 |
| Bristol Myers Squibb | 4 | $67 |
| Regeneron Healthcare Solutions, Inc. | 4 | $62 |
| Fresenius Kabi USA, LLC | 3 | $58 |
| ANI Pharmaceuticals, Inc. | 3 | $50 |
| Radius Health, Inc. | 2 | $33 |
| Sobi, Inc | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bimzelx$110
How this compares
$8,399 in reported general payments places this provider in the 60th percentile of 48 rheumatology providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 105 | $773,691 |
| RinvoqUpadacitinib | 90 | $582,730 |
| Humira(Cf)Adalimumab | 74 | $502,835 |
| Xeljanz XrTofacitinib Citrate | 87 | $485,440 |
| EnbrelEtanercept | 64 | $466,369 |
| Simponi AriaGolimumab | 63 | $434,038 |
| HumiraAdalimumab | 52 | $350,253 |
| OrenciaAbatacept/Maltose | 73 | $336,298 |
| ActemraTocilizumab | 134 | $332,348 |
| Humira(Cf) PenAdalimumab | 47 | $310,449 |
| OrenciaAbatacept | 50 | $293,787 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 30 | $225,510 |
| BenlystaBelimumab | 48 | $199,575 |
| KevzaraSarilumab | 45 | $191,034 |
| Orencia ClickjectAbatacept | 26 | $146,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf), Humira | $1,971 | $1,435,819216 claims |
| E.r. Squibb & Sons, L.L.C.Orencia, Orencia | $257 | $630,084123 claims |
| AmgenEnbrel, Otezla | $1,819 | $606,33993 claims |
| Johnson & JohnsonSimponi Aria | $459 | $434,03863 claims |
| GSKBenlysta | $274 | $199,57548 claims |
| SanofiKevzara | $108 | $191,03445 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,042 | $78,61714 claims |
| Lilly USA, LLCOlumiant | $315 | $35,62013 claims |
| Fresenius Kabi USA, LLCSodium Chloride | $58 | $838233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 48 rheumatology providers in Arkansas.
Other rheumatology in Lowell
- Russell BranumFort Smith$102K
- Cummins LueLittle Rock$76K
- Shailendra SinghSearcy$67K
- Christopher SonntagFayetteville$32K
- Jasen ChiLittle Rock$30K
- Richard HoukLittle Rock$25K
- Noha MohamedConway$19K
- Columbus BrownLittle Rock$18K
- David PetrosFayetteville$17K
- Renee Peterkin-MccalmanLittle Rock$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.